Background The optimal therapy for preventing recurrent stroke in people with cryptogenic
stroke and patent foramen ovale (PFO) has not been defined. The choice between medical …

We pooled available data on follow-up events in patients with patent foramen ovale and
cryptogenic stroke to evaluate the net clinical benefit of different therapeutic strategies …

Background In patients with cryptogenic stroke, transcatheter (TC) closure of a patent
foramen ovale (PFO) has not been shown to better prevent recurrent vascular events than …

Background Patent foramen ovale (PFO) might be a risk factor for unexplained
(“cryptogenic”) stroke or transient ischemic attack (TIA). We sought to determine the efficacy …

Background and Purpose—Previous systematic reviews and meta-analyses compared the
efficacy and safety of patent foramen ovale (PFO) closure versus medical treatment in …

Objectives We sought to perform a meta‐analysis of randomized controlled trials (RCTs)
comparing percutaneous patent‐foramen‐ovale (PFO) closure with medical therapy for …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: The optimal strategy for preventing recurrent stroke in patients …

Objective To examine the relative impact of three management options in patients aged< 60
years with cryptogenic stroke and a patent foramen ovale (PFO): PFO closure plus …

Background There is an association between cryptogenic stroke and patent foramen ovale
(PFO). The optimal treatment strategy for secondary prevention remains unclear. The …

Objective Current guidelines report no benefit for patent foramen ovale (PFO) closure
compared to medical treatment in patients with cryptogenic ischemic stroke (IS) or TIA. Two …